Tarsons Products Ltd
Tarsons Products Ltd. (TPL) is an Indian labware company engaged in the designing, development, manufacturing, and marketing of 'consumables', 'reusables' and 'others' including benchtop equipment, used in various laboratories across research organizations, academia institutes, pharmaceutical companies, Contract Research Organizations, Diagnostic companies, and hospitals[1]
- Market Cap ₹ 2,001 Cr.
- Current Price ₹ 375
- High / Low ₹ 544 / 349
- Stock P/E 41.5
- Book Value ₹ 118
- Dividend Yield 0.53 %
- ROCE 10.2 %
- ROE 8.62 %
- Face Value ₹ 2.00
Pros
Cons
- The company has delivered a poor sales growth of 9.18% over past five years.
- Company might be capitalizing the interest cost
- Dividend payout has been low at 6.92% of profits over last 3 years
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Miscellaneous
Part of BSE Allcap BSE SmallCap BSE Healthcare
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|
179 | 176 | 229 | 301 | 283 | 277 | 293 | |
107 | 107 | 125 | 148 | 153 | 174 | 196 | |
Operating Profit | 72 | 69 | 103 | 153 | 130 | 103 | 97 |
OPM % | 40% | 39% | 45% | 51% | 46% | 37% | 33% |
6 | 4 | 5 | 8 | 12 | 14 | 25 | |
Interest | 7 | 6 | 3 | 4 | 4 | 10 | 15 |
Depreciation | 15 | 14 | 14 | 22 | 29 | 38 | 41 |
Profit before tax | 56 | 53 | 92 | 135 | 109 | 69 | 65 |
Tax % | 30% | 24% | 25% | 25% | 26% | 26% | |
39 | 41 | 69 | 101 | 81 | 51 | 48 | |
EPS in Rs | 2,027.06 | 2,108.74 | 3,583.25 | 18.92 | 15.17 | 9.63 | 9.06 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 21% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 9% |
3 Years: | 7% |
TTM: | 8% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 6% |
3 Years: | -9% |
TTM: | -21% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -18% |
1 Year: | -21% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 18% |
3 Years: | 16% |
Last Year: | 9% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|
Equity Capital | 0.19 | 0.20 | 0.19 | 11 | 11 | 11 | 11 |
Reserves | 135 | 197 | 244 | 479 | 559 | 610 | 618 |
65 | 36 | 34 | 22 | 111 | 257 | 244 | |
12 | 15 | 18 | 33 | 46 | 76 | 109 | |
Total Liabilities | 212 | 249 | 296 | 544 | 726 | 953 | 982 |
89 | 92 | 120 | 189 | 225 | 252 | 399 | |
CWIP | 7 | 19 | 22 | 32 | 119 | 267 | 217 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
116 | 137 | 153 | 323 | 382 | 434 | 366 | |
Total Assets | 212 | 249 | 296 | 544 | 726 | 953 | 982 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|
51 | 64 | 68 | 83 | 76 | 105 | |
-34 | -26 | -64 | -138 | -179 | -296 | |
-18 | -14 | -27 | 130 | 85 | 136 | |
Net Cash Flow | -0 | 25 | -23 | 75 | -18 | -55 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|
Debtor Days | 91 | 79 | 75 | 79 | 85 | 94 |
Inventory Days | 333 | 365 | 277 | 478 | 642 | 528 |
Days Payable | 14 | 44 | 35 | 75 | 54 | 42 |
Cash Conversion Cycle | 409 | 400 | 317 | 482 | 672 | 580 |
Working Capital Days | 160 | 149 | 108 | 165 | 205 | 179 |
ROCE % | 27% | 37% | 35% | 19% | 10% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Credit Rating
1d - CARE Ratings downgraded Tarsons' bank loan facilities.
-
Board Meeting Intimation for Considering And Approving The Unaudited Standalone &
Consolidated Financial Results For The Third Quarter And Nine Months Ended 31St December, 2024
31 Jan - Notice of Board Meeting for Q3 financial results.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
10 Jan - DP) Regulations, 2018 for the quarter ended 31st December, 2024
-
Closure of Trading Window
23 Dec 2024 - Closure of trading window until financial results announcement.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
29 Nov 2024 - Officials of the Company will be attending the Investors/ Analysts (Participants) Conference as per the details in the attachment.
Annual reports
Concalls
-
Nov 2024Transcript PPT REC
-
Aug 2024Transcript PPT REC
-
Aug 2024TranscriptNotesPPT
-
Jun 2024Transcript PPT
-
Feb 2024Transcript PPT REC
-
Feb 2024TranscriptNotesPPT
-
Dec 2023TranscriptPPTREC
-
Nov 2023Transcript PPT REC
-
Aug 2023Transcript PPT
-
Jun 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
Jun 2022Transcript PPT
-
Feb 2022Transcript PPT
India’s Leading Labware Company[1]
One of the leading Indian labware company engaged in designing, development, manufacturing and marketing of consumables, reusables and others (including benchtop
equipment & instruments)